Xiangyu Medical Reports 2024 Revenue of RMB 744 Million Amid Strategic Expansion in BCI and Rehabilitation Robotics

Call for Partners: 2025 Global Surgical Robotics Conference

# Financial Data

Company's Revenue in 2024744 millionYuan (YoY -0.17%), Net Profit Attributable to Shareholders103 millionYuan (YoY -54.68%), Non-GAAP Net Profit Attributable to Shareholders90 millionYuan (YoY -55.90%).

According to this calculation,Revenue of 237 million yuan achieved in Q4 2024 (YoY +16.74%)Net profit attributable to母公司 shareholders was 0.30 billion yuan (a year-on-year decrease of -38.45%), and the net profit attributable to母公司 shareholders after deducting non-recurring gains and losses was 0.26 billion yuan (a year-on-year decrease of -35.06%).

In 2024, the company established the Shanghai Rehabilitation Robotics Laboratory.Established the Sun-BCI Lab Brain-Computer Interface LaboratoryFocusing on five major research and development directions, including EEG acquisition devices, brain-controlled products, products for daily scenarios, self-developed algorithms, and brain biomedicine. Among these, the EEG machine, EEG acquisition devices, and mental health-related products are expected to obtain medical device registration certificates by the second half of 2025.

Split in 2024

By Business:Revenue from physical rehabilitation medical devices was 504 million yuan (YoY +9.85%); revenue from rehabilitation training equipment was 165 million yuan (YoY -19.89%); revenue from rehabilitation assessment equipment was 28 million yuan (YoY -21.92%); revenue from accessory products was 37 million yuan (YoY +1.18%); revenue from other businesses was 10 million yuan (YoY +20.69%).

The Company Achieved Revenue in the First Quarter of 2025186 millionRMB (YoY +10.02%), net profit attributable to shareholders RMB 23 million (YoY -41.26%), non-recurring net profit attributable to shareholders RMB 19 million (YoY -48.75%).The company continues to increase R&D investment in areas such as brain-computer interface, rehabilitation robots, and AI healthcare, while further optimizing the clinical rehabilitation integrated marketing team. As a result, R&D expenses and sales expenses have increased, leading to a decrease in net profit attributable to shareholders of the listed company.

# About Sunnyou Medical

Sunnyou Medical was founded in 2002, with a registered capital of 160 million yuan, and is a company focused onResearch, Development, Production, Sales and Service of Rehabilitation Medical Devicesa national high-tech enterprise. The company was listed on the Sci-Tech Innovation Board in March 2021, and its registered address is in Anyang City, Henan Province, China.

The company provides a full range of rehabilitation products and comprehensive solutions for medical institutions at all levels, elderly care facilities, and families across China.Its products mainly include rehabilitation assessment equipment, rehabilitation training equipment, rehabilitation physiotherapy equipment, rehabilitation aids, and rehabilitation nursing equipment.As a leading enterprise in research and development within China's rehabilitation medical device industry, Sunnyou ranked among the top three in the 2024 Comprehensive Ranking of R&D Strength for Medical Device Companies in China.

The company highly values R&D work,As of the end of June 2024, a total of 1,702 patents have been accumulated.In 2024, the company's R&D investment was 152,022,069.57 yuan, accounting for 20.45% of the total operating revenue.The company has successfully established the Sun-BCI Lab brain-computer interface laboratory,And established a product system with four major categories.

The company continues to deepen its profound layout in the domestic market and actively expand into the global market. In 2024, the company's sales in areas such as military business, exports, and out-of-hospital institutions showed a growth trend.